Wedbush Reaffirms “Outperform” Rating for Aclaris Therapeutics (NASDAQ:ACRS)
Wedbush reissued their outperform rating on shares of Aclaris Therapeutics (NASDAQ:ACRS – Free Report) in a report released on Monday morning,RTT News reports. The brokerage currently has a $8.00 price objective on the biotechnology company’s stock. Other equities research analysts have also issued reports about the company. HC Wainwright reaffirmed a “buy” rating and issued […]
Wedbush reissued their outperform rating on shares of Aclaris Therapeutics (NASDAQ:ACRS – Free Report) in a report released on Monday morning,RTT News reports. The brokerage currently has a $8.00 price objective on the biotechnology company’s stock. Other equities research analysts have also issued reports about the company. HC Wainwright reaffirmed a “buy” rating and issued […]
